Gyre Therapeutics
GYRE
28 hedge funds and large institutions have $796K invested in Gyre Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 9 reducing their positions, and 13 closing their positions.
13% more capital invested
Capital invested by funds: $708K → $796K (+$88.7K)
0.31% less ownership
Funds ownership: 0.71% → 0.4% (-0.31%)
26% less funds holding
Funds holding: 38 → 28 (-10)
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$11.6K |
| 2 |
Morgan Stanley
New York
|
+$9.01K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6.21K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.91K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$3.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$56K |
| 2 |
Bank of New York Mellon
New York
|
-$41.5K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$27.6K |
| 4 |
Renaissance Technologies
New York
|
-$24.3K |
| 5 |
BSW
Buckingham Strategic Wealth
Clayton,
Missouri
|
-$22.7K |
GYRE Hedge Fund Activity: Q2 2023 in Review
28 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q2 2023, worth a combined $796K — up 13% from $708K a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of GYRE and 3 opened new positions — a net loss of 10 holders — while 9 trimmed existing stakes and 3 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $11.6K. The largest seller was Millennium Management, exiting entirely with an estimated $56K sold.
- 28 institutional investors held Gyre Therapeutics (GYRE) as of Q2 2023, down from 38 in Q1 2023.
- Funds reported $796K of Gyre Therapeutics stock for Q2 2023, up 13% quarter-over-quarter.
- 3 funds opened new Gyre Therapeutics positions in Q2 2023 and 13 closed out, a net change of -10 holders.
- The largest Gyre Therapeutics buyer in Q2 2023 was Virtu Financial, an estimated $11.6K added.
- The largest Gyre Therapeutics seller in Q2 2023 was Millennium Management, an estimated $56K sold.
Based on aggregated 13F filings for Q2 2023.